hotspot -WSS

hotspot

author：focus 2025-09-27 16:48:42 - browse：3

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Violet CEO on training clinicians to promote more inclusive care

explore

focus

WSS

Christmas in the PICU brings some surprising joy

Bristol Myers buys into radiopharmaceuticals with RayzeBio

ALS treatment from Biogen, Ionis fails in study

Prime Medicine, Myeloid Therapeutics clash over genome

Lilly’s weekly insulin works as well as daily products, new studies show

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Wikipedia

hotspot

knowledge

Peter Hotez and the public health issue of online harassment

ALS treatment from Biogen, Ionis fails in study

Peter Hotez and the public health issue of online harassment

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Medicare details structure of new drug price negotiation program

Abbott's new stent may help patients with peripheral artery disease

How one medical school became remarkably diverse

Free medical tuition alone isn't enough to close gaps in primary care

Affirmative action in medical school literally saved lives

STAT series 'Denied by AI' wins major journalism prizes

hotspot

STAT series 'Denied by AI' wins major journalism prizes

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Prime Medicine, Myeloid Therapeutics clash over genome

Virtual care provider acquires bankrupt Pear's prescription apps

Hottest summer in 2,000 years puts focus on extreme heat, health

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

explore

explore

focus

entertainment